- Home
- TSAT vs AQST Comparison
TSAT vs AQST Comparison
Compare TSAT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | AQST |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.9M | 707.6M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TSAT | AQST |
|---|---|---|
| Price | $30.45 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 119.5K | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,440,552.00 | $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.31 | $2.12 |
| 52 Week High | $36.85 | $7.55 |
Technical Indicators
Market Signals| Indicator | TSAT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 48.23 |
| Support Level | $28.19 | $6.16 |
| Resistance Level | $33.51 | $6.59 |
| Average True Range (ATR) | 1.86 | 0.30 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 47.16 | 45.92 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.